Providence Medical Foundation

Running trials

• Not yet recruiting

  A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity

  NCT07919405· Phase 3· Source

• Recruiting

  FT839 in Autoimmune Diseases

  NCT07800871· Phase 1/2· Source

• Recruiting

  AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

  NCT07720271· Phase 3· Source

• Recruiting

  A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

  NCT07570862· Phase 2· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Source

• Recruiting

  Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

  NCT07227298· Phase 1/2· Source

• Recruiting

  Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

  NCT06745908· Phase 3· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Source

• Active, not recruiting

  A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

  NCT07076199· Phase 3· Source

• Recruiting

  Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

  NCT06757634· Phase 3· Source

• Recruiting

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· Phase 3· Source

• Recruiting

  A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  NCT06875310· Phase 3· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

  NCT06644781· Phase 3· Source

• Recruiting

  Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

  NCT06806033· Phase 2· Source

• Active, not recruiting

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· Phase 3· Source

• Recruiting

  A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors

  NCT06747585· Phase 1/2· Source

• Recruiting

  A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

  NCT06246916· Phase 3· Source

• Active, not recruiting

  N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

  NCT06061809· Phase 2· Source

• Active, not recruiting

  Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

  NCT06293365· Phase 2· Source

• Recruiting

  Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

  NCT06425926· Phase 1/2· Source

• Active, not recruiting

  Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

  NCT06235151· Phase 3· Source

• Recruiting

  A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

  NCT06308978· Phase 1· Source

• Active, not recruiting

  A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

  NCT06012435· Phase 3· Source

• Recruiting

  A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

  NCT06072482· Phase 4· Source

• Active, not recruiting

  A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

  NCT06005740· Phase 1· Source

• Active, not recruiting

  A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

  NCT05985915· Phase 3· Source

• Active, not recruiting

  First in Human Study of TORL-3-600 in Participants With Advanced Cancer

  NCT05948826· Phase 1· Source

• Active, not recruiting

  To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

  NCT05468489· Phase 2· Source

• Recruiting

  Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

  NCT05254171· Phase 2/3· Source

• Active, not recruiting

  Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

  NCT05349214· Phase 3· Source

• Active, not recruiting

  A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

  NCT05288166· Phase 3· Source

• Active, not recruiting

  Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

  NCT05169567· Phase 3· Source

• Active, not recruiting

  177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

  NCT05204927· Phase 3· Source

• Recruiting

  Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

  NCT05098132· Phase 1/2· Source

• Active, not recruiting

  A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

  NCT05163028· Phase 1· Source

• Recruiting

  First in Human Study of TORL-1-23 in Participants With Advanced Cancer

  NCT05103683· Phase 1· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

  NCT04963296· Phase 3· Source

• Recruiting

  A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  NCT04389632· Phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer8 recruiting
• ANCA-associated vasculitis3 recruiting
• Gastric and oesophageal cancer3 recruiting
• Lupus (SLE)3 recruiting
• Head and neck cancer2 recruiting
• Melanoma2 recruiting
• Obesity2 recruiting
• Ovarian cancer2 recruiting
• Pancreatic cancer2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Colorectal cancer1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometrial cancer1 recruiting
• Follicular lymphoma1 recruiting
• High blood pressure1 recruiting
• Hodgkin lymphoma1 recruiting
• Metastatic breast cancer1 recruiting
• Rheumatoid arthritis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· Phase 3· Source

• Completed

  Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer

  NCT06235099· Phase 3· Source

• Completed

  A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

  NCT05394519· Phase 3· Source

• Completed

  A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

  NCT05514535· Phase 3· Source

• Terminated

  Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

  NCT05267106· Phase 2· Source

• Terminated

  Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer

  NCT04958785· Phase 2· Source

• Terminated

  A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

  NCT05001282· Phase 1/2· Source

• Completed

  Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

  NCT03904693· Phase 3· Source

• Completed

  Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

  NCT03377491· Phase 3· Source

• Completed

  A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

  NCT03412773· Phase 3· Source